June 21, 2021 -- Arrowhead Pharmaceuticals and Horizon Therapeutics are collaborating on ARO-XDH, a previously undisclosed discovery-stage investigational RNA interference (RNAi) therapeutic.
The drug could potentially treat people with uncontrolled gout as it targets the primary source of serum uric acid.
Arrowhead will handle the drug's preclinical stages of development and Horizon will receive a worldwide exclusive license. Horizon will be wholly responsible for clinical development and commercialization.
Horizon will pay Arrowhead $40 million upfront and Arrowhead is eligible to receive up to $660 million in potential development, regulatory, and commercial milestones. The firm is also eligible to receive royalties in the low- to mid-teens range on net product sales, according to a press release.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
